ADAP Advocacy Unveils Infographic on 340B Drug Pricing Program

Infographic Exposes Hospitals' Failure to Serve Low-Income Patients


    WASHINGTON, DC, December 19, 2025 -- ADAP Advocacy today, as part of its 340B Project, published an infographic that exposes declining charity care by hospitals and its impact on patients, especially minorities. The infographic complements the recently released commercial and is part of the ongoing 340B national advocacy campaign, "Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?"

The '340B Too Big to Fail – Charity Care' infographic examines the requirements for hospitals to provide free care and financial aid to poor patients, also known as charity care. What's particularly striking is that charity care continues to decline year after year. Patients owe at least $220 billion in medical debt, and nearly 75% of it is owed to hospitals, with Black and Hispanic communities disproportionately impacted.

The infographic can be downloaded online here: https://www.adapadvocacy.org/publications.html#i.

To learn more about ADAP Advocacy, the 340B Drug Pricing Program, or the new '340B Too Big to Fail' infographics, please email info@adapadvocacy.org.

The ADAP Advocacy mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.

# # #

Contact Information
Brandon Macsata
ADAP Advocacy

Washington, DC
USA
Voice: 305-519-4256
Website: Visit Our Website
Blog: Visit Our Blog

Disclaimer
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact Dragstrip Communications Newswire. We are unable to assist you with any information regarding this release. Dragstrip Communications Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.